Rocket Lab Corp 8-K

What Happened
On March 17, 2026, Rocket Lab Corporation announced it entered into an Equity Distribution Agreement with a group of sales agents led by BofA Securities, Morgan Stanley, Goldman Sachs and others, under which the company may offer and sell up to $1,000,000,000 of its common stock. The agreement also contemplates related forward sale arrangements (including “Initially Priced Forward Transactions” and “Collared Forward Transactions” with certain counterparties) that hedge or defer when Rocket Lab receives proceeds. The sales will be made under Rocket Lab’s shelf registration on Form S‑3 (initially filed March 11, 2025 and amended May 27, 2025) and a prospectus supplement filed March 17, 2026.

Key Details

• Offering capacity: up to $1,000,000,000 of common stock through sales agents or via forward sale transactions.
• Sales agents include major firms such as BofA Securities, Morgan Stanley, Goldman Sachs, Deutsche Bank and others.
• Commissions/fees: sales agents and forward sellers may receive up to 2.00% commission; certain forward structures reflect a commission deducted from amounts payable to the company.
• Forward sale mechanics: Initially Priced Forward Transactions and Collared Forward Transactions may delay or change when/if the company receives cash; the company could receive cash at settlement, receive shares, or owe cash/shares depending on election and settlement results. Borrowing of shares by forward purchasers may be limited; if borrowing fails or costs are too high, the number of shares hedged (and underlying the forward) can be reduced to zero.

Why It Matters
This filing gives Rocket Lab flexible access to raise up to $1 billion of capital over time, which can support operations, growth or balance‑sheet needs. For investors, the program represents potential future dilution because new shares could be issued when sales settle. The use of forward sale agreements means proceeds and the timing of dilution may be deferred or structured (including possible cash or share settlement), so the immediate cash benefit to the company is not guaranteed for all transactions. Commissions and fees (up to 2%) and the possibility that forward counterparties cannot borrow hedging shares are additional factors that can affect net proceeds and timing.